Tumor growth is associated with profound metabolic and neurochemical alterations, which can lead to the onset of anorexia−cachexia syndrome. Anorexia is defined as the loss of the desire to eat, while ...

SOLANA BEACH, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (ARTL) (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to ...

Consistent Improvements in Weight Gain, Lean Body Mass, and Activity were Observed Across Treated Patients including +6.4% Mean Weight Gain at 12 Weeks vs −5.4% Mean Weight Loss on Placebo The Phase 2 ...

A dual cannabinoid agonist drug candidate is being investigated for its potential in treating wasting syndrome in cancer patients. It demonstrated a weight gain in patients who took the drug versus a ...

Patients treated with ART27.13 showed consistent improvements in weight, lean body mass, and activity While clinical benefits were observed in all treated cohorts, the best outcomes in CAReS were ...

The optimal therapy for anorexia and cachexia is curing the underlying cancer. [23] Unfortunately, this goal is often not attainable with currently available treatments. Thus, an integrated ...

Catalyst for Advancing Discussions with Pharmaceutical Companies that have Expressed Interest in ART27.13 for CACS Consistent Improvements in Weight Gain, Lean Body Mass, and Activity were Observed ...

SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop ...